Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer
The epirubicin/docetaxel combination is one of the most active and best tolerated taxane/anthracycline combinations. In this phase II trial, we will further evaluate the feasibility, safety and effectiveness of the docetaxel/epirubicin combination, when administered as first-line treatment for metastatic breast cancer.
Breast Cancer
DRUG: Docetaxel|DRUG: Epirubicin
Clinical response rate of the docetaxel/epirubicin combination in the first-line treatment of patients with metastatic breast cancer
Safety of the docetaxel/epirubicin combination in the first-line treatment of patients with metastatic breast cancer
Upon determination of eligibility, all patients will receive:

Docetaxel + Epirubicin

Both drugs will be repeated at 21-day intervals